"Obesity"

155,649 resultsPro users have access to +21833 Systematic Reviews

Filter Results
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
          • Pro
                    • Pro

                            Clinical Area Pro

                            Further Refinement
                            User Guide

                            User Guide

                            1
                            2025National Institute for Health and Care Excellence - Clinical Guidelines
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Overweight and obesity management Overweight and obesity management NICE guideline Published: 14 January 2025 www.nice.org.uk/guidance/ng246 © NICE 2025. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Overweight and obesity management (NG246)© NICE 2025. All rights reserved. Subject to Notice of rights ( 2 of179 Contents Overview
                            2
                            Endoscopic sleeve gastroplasty for obesity Endoscopic sleeve gastroplasty for obesity Interventional procedures guidance Published: 22 February 2024 www.nice.org.uk/guidance/ipg783 Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take and procedures. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. 1 Recommendations 1.1 Use endoscopic sleeve gastroplasty as an option to treat obesity in adults with standard arrangements in place for clinical governance, consent
                            Subscribe to Trip PRO for an enhanced experience
                            • Access to millions of Full-text articles where avaliable
                            • Unlock 100,000+ extra articles with Systematic Reviews
                            • Further Filtering Options
                            • No adverts
                            • Advanced Search Ability
                            • Enhanced SmartSearch showing unlimited related articles
                            Read more about Trip PRO
                            3
                            Tirzepatide for managing overweight and obesity Tirzepatide for managing overweight and obesity Technology appraisal guidance Published: 23 December 2024 www.nice.org.uk/guidance/ta1026 © NICE 2025. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Tirzepatide for managing overweight and obesity (TA1026)© NICE 2025. All rights reserved. Subject to Notice of rights ( 2 of54 Contents 1 Recommendations
                            4
                            2025NIHR HTA programme
                            Review Analysis
                            Appears Promising
                            ?
                            60-month follow-up of Long Limb vs. Standard Limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT 60-month follow-up of Long Limb vs. Standard Limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Journals Library Search Journals diabetes and obesity: the LONG LIMB RCT 1. Journals Library 2. Efficacy and Mechanism Evaluation 3. 60-month follow-up of Long Limb vs. Standard Limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT * Type: Research Article Our publication formats * Authors: Saleem Ansari, Anna Kamocka, Tina Mazaheri, Ibiyemi Ilesanmi, Lara Jimenez-Pacheco, Kleopatra Alexiadou, Joanna Tan
                            5
                            2023National Institute for Health and Care Excellence - Clinical Guidelines
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Obesity: identification, assessment and management Obesity: identification, assessment and management Clinical guideline Published: 27 November 2014 www.nice.org.uk/guidance/cg189 © NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 8 September 2022Your responsibility The recommendations in this guideline and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Obesity: identification, assessment and management (CG189)© NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 8 September 2022Page 2of 56Contents Overview
                            6
                            2024NIHR HTA programme
                            Review Analysis
                            Appears Promising
                            ?
                            Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * Policies
                            7
                            Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome Highly specialised technologies guidance Published: 22 May 2024 www.nice.org.uk/guidance/hst31 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance represent the view of NICE, arrived inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)© NICE 2024. All rights reserved. Subject to Notice of rights ( 2 of41 Contents 1
                            8
                            2025Health Quality Ontario
                            Bariatric Surgery for Adults With Class I Obesity and Difficult-to-Manage Type 2 Diabetes: A Health Technology Assessment Normal development depends on both the timing of fertilization and gamete quality, especially in assisted reproductive procedures. Recent studies of the proteins involved in the polyspermy block and cell cycle progression provide a cellular and biochemical basis for the short
                            9
                            Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) Technology appraisal guidance Published: 13 July 2023 www.nice.org.uk/guidance/ta910 © NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms -and-conditions#notice-of-rights).Contents Advice ................................................................................................................................3 Information ..................................................................................................................................3 Semaglutide for managing overweight and obesity in young people aged 12 to 17 years
                            10
                            Semaglutide for managing overweight and obesity Semaglutide for managing overweight and obesity Technology appraisal guidance Published: 8 March 2023 www.nice.org.uk/guidance/ta875 © NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility The recommendations in this guidance represent the view of NICE, arrived inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Semaglutide for managing overweight and obesity (TA875)© NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice
                            11
                            2024Health Quality Ontario
                            Bariatric Surgery for Adults With Class I Obesity and Difficult-to-Manage Type 2 Diabetes: A Health Technology Assessment Skip to main contentAn official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationVolume 23(8);  2023Bariatric Surgery for Adults With Class I Obesity and Difficult-to-Manage Type 2 Diabetes
                            12
                            2024Prescrire
                            Semaglutide in secondary cardiovascular prevention in overweight or obese patients Prescrire IN ENGLISH - Spotlight ''Semaglutide in secondary cardiovascular prevention in overweight or obese patients'', 1 June 2024 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics subscription * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Semaglutide in secondary cardiovascular prevention in overweight or obese patients SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90
                            13
                            2023BMJ Best Practice
                            Obesity in children Skip to main contentSkip to searchLog inEnglish#{autosuggest.search}#{autosuggest.search}Obesity in children MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:15 Oct 2023Last updated:10 Nov 2023SummaryObesity in children has increased in recent decades. Causes are multi-factorial including biological, genetic disposition, behavioural and environmental influences.Calculating body mass index (BMI) is the most widely accepted method of screening for obesity in children. Abnormal BMI cut-offs in children are determined by age- and sex-specific percentiles.Impaired glucose tolerance and type 2 diabetes mellitus are prevalent in children with obesity.Preventing excessive weight gain in children is of paramount importance in confronting the obesity epidemic, as obesity
                            14
                            2023BMJ Best Practice
                            Obesity in adults Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageObesity in adults MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:14 May 2023Last updated:13 Jun 2023IMPORTANT UPDATESSummaryPresentation of obesity may range from asymptomatic to presentation complicated by multiple comorbidities, including cancer, coronary artery disease, diabetes, hypertension, gout, obstructive sleep apnoea, and osteoarthritis. Worldwide, it is estimated that nearly 4 million people die each year as a consequence of weight-related comorbidities.The definitive test for obesity remains the body mass index (BMI; obesity is defined as a BMI ≥30 kg/m²).Central or abdominal obesity has a stronger
                            15
                            2021National Institute for Health and Care Excellence - Clinical Guidelines
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s NICE guideline Published: 20 August 2021 www.nice.org.uk/guidance/ng202 © NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s(NG202)© NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk
                            16
                            Setmelanotide for treating obesity caused by LEPR or POMC deficiency Setmelanotide for treating obesity caused by LEPR or POMC deficiency Highly specialised technologies guidance Published: 6 July 2022 www.nice.org.uk/guidance/hst21 © NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility Your responsibility impact of implementing NICE recommendations wherever possible. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)© NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of36Contents Contents 1 Recommendations
                            17
                            2025American Gastroenterological Association Institute
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Obesity toolkit Obesity toolkit - American Gastroenterological AssociationSkip to contentAGA Family of Websites: Gastro.orgAGA Family of Websites: Gastro.org Renew for 2025 Login here Create Account Login My AGA Gastro.org * AGA Journals * AGA University * AGA Research Foundation * AGA Community * AGA Job Board * Join AGA * Log In Gastro.org * AGA Journals * AGA University * AGA Research is needed to survive. But too much fat can be harmful to a patient’s body. Obesity can cause low-level inflammation throughout the body, harming blood vessels, muscles (including the heart), and organs (like the liver and pancreas), raise cancer risk, and cause joint and muscle pain as well as obstructive sleep apnea. Treatment for obesity includes lifestyle changes, such as nutrition and exercise
                            18
                            2025NICE Clinical Knowledge Summaries (Accessible in UK Only)
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Obesity - Identification and classification Identification and classification | Diagnosis | Obesity | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Obesity 5. Diagnosis 6. Identification and classification Obesity: How should I confirm if a person is overweight or obese?Last revised in February 2025 Identification and classification * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Diagnosis
                            19
                            2025NICE Clinical Knowledge Summaries (Accessible in UK Only)
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Obesity - Tirzepatide Tirzepatide | Prescribing information | Obesity | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1. NICE 2. CKS 3. Health topics A to Z 4. Obesity 5. Prescribing information 6. Tirzepatide Obesity: TirzepatideLast revised in February 2025 Tirzepatide * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Diagnosis * Management * Prescribing information * Orlistat * Tirzepatide * Supporting evidence * How this topic
                            20
                            2025NICE Clinical Knowledge Summaries (Accessible in UK Only)
                            Trip Score
                            NarrativeNarrative based
                            EvidenceEvidence based
                            ?
                            Obesity - Definition Definition | Background information | Obesity | CKS | NICE * Skip to content * Accessibility help Search CKS…Skip to contentMenu * Guidance * Standards and indicators * Life sciences * British National Formulary (BNF) * British National Formulary for Children (BNFC) * Clinical Knowledge Summaries (CKS) * * Health topics A to Z * Specialities * What's new * About CKS * About 1 . NICE 2. CKS 3. Health topics A to Z 4. Obesity 5. Background information 6. Definition Obesity: What is it?Last revised in February 2025 Definition * Summary * Have I got the right topic? * How up-to-date is this topic? * Goals and outcome measures * Background information * Definition * Causes and risk factors * Prevalence * Complications * Prognosis * Diagnosis * Management * Prescribing